INTEREST AND IMPLEMENTATION OF RAPID DARATUMUMAB INFUSION DURING THE HEALTH CRISIS
5PSQ-167
ANALYSIS OF FIRSTLINE TREATMENT IN THE ELDERLY WITH METASTATIC COLORECTAL CANCER
5PSQ-166
MANAGEMENT OF TOXICITIES RELATED TO CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN METASTATIC BREAST CANCER
5PSQ-165
INCIDENCE AND MANAGEMENT OF ETOPOSIDE HYPERSENSITIVITY IN PAEDIATRIC PATIENTS
5PSQ-164
REAL SAFETY OF DARATUMUMAB IN MYELOMA MULTIPLE
5PSQ-163
INCIDENCE OF NEUTROPENIA AND EFFECTIVENESS OF PALBOCICLIB IN CLINICAL PRACTICE IN METASTATIC BREAST CANCER AFTER 4 YEARS OF USE
5PSQ-162
METHOTREXATE-INDUCED MYELITIS IN A CAUCASIAN GIRL WITH LYMPHOBLASTIC LYMPHOMA AND PHARMACOGENETIC STUDY: CASE REPORT
5PSQ-161
EFFECTIVENESS AND SAFETY OF PALBOCICLIB AND RIBOCICLIB
5PSQ-160
MOGAMULIZUMAB EXPERIENCE IN ADVANCED SEZARY SYNDROME: A CASE REPORT
5PSQ-159
PALBOCICLIB SAFETY IN METASTATIC BREAST CANCER
5PSQ-158
OFF-LABEL USE OF PEMBROLIZUMAB IN PD-L1 POSITIVE METASTATIC ANAPLASTIC THYROID CARCINOMA: A CASE REPORT
5PSQ-157
EXPENDITURE AND CONSUMPTION DESCRIPTIVE ANALYSIS: RITUXIMAB ORIGINATOR VERSUS BIOSIMILAR IN AN ITALIAN DISTRICT
5PSQ-156
COMPLIANCE OF RECOMMENDATIONS FOR THE PREVENTION OF HEPATITIS B VIRUS REACTIVATION DURING DARATUMUMAB TREATMENT
5PSQ-155
ASSISTANCE PRESSURE IN ONCOHAEMATOLOGICAL DISPENSATION AREA DURING THE COVID PANDEMIC
5PSQ-154
DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE AS PREDICTORS OF SEVERE FLUOROPYRIMIDINE ASSOCIATED TOXICITY
